Total
0
Shares
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating
CEO & Managing Director, Dr Tony Keating
Source: Courier Mail
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ResApp Health (RAP) has signed a memorandum of understanding (MoU) with RB to develop an app that uses its ResAppDx-EU respiratory test
  • RB is a global health, hygiene, and nutrition products manufacturer that is known for brands such as Dettol, Nurofen, Clearasil, and Air Wick
  • Under this MoU, both companies will work together to develop a prototype app which will be used by customers to assess their respiratory symptoms
  • If a joint development is not signed within six months, then either party can terminate the partnership
  • ResApp is steady on the market this morning and shares are trading for 19 cents each

ResApp Health (RAP) has signed a memorandum of understanding with RB to develop an app that uses its ResAppDx-EU respiratory test.

RB is a global health, hygiene, and nutrition products manufacturer that is known for brands such as Dettol, Nurofen, Clearasil, and Air Wick.

Under this MoU, both companies will work together to build and test a prototype app which will be used by customers to self-assess — or assess with the aid of a pharmacist — their respiratory symptoms.

This partnership will make use of ResApp’s regulatory-approved ResAppDx-EU test, which is used for the diagnosis of multiple respiratory problems.

All users have to do is cough into the phone and the machine learning algorithms analyse the sounds to diagnose the disease and provide quick and accurate information.

It runs on smartphones and does not need any additional hardware or accessories to be used.

If a joint development is not signed within six months, then either party can terminate the partnership.

ResApp is steady on the market this morning and shares are trading for 19 cents each at 10:33 am AEST.

RAP by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.